Idorsia raises Sfr505m through share sale and CB to fund R&D

Idorsia, the Swiss biopharmaceutical company, has raised Sfr505m ($503.82m) to finance advanced clinical trials after a simultaneous share and convertible bond sale overnight in Zurich.

  • By Aidan Gregory
  • 11 Jul 2018

Credit Suisse and Goldman Sachs ran the books on both deals, which were launched after the market closed on Tuesday evening.

The Sfr305m share capital increase consisted of 11.9m shares, while the Sfr200m senior unsecured bonds are due in 2024 and had an initial coupon range of ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 344,931.23 1345 8.09%
2 JPMorgan 341,263.25 1468 8.00%
3 Bank of America Merrill Lynch 306,817.51 1057 7.19%
4 Barclays 256,761.63 967 6.02%
5 Goldman Sachs 227,538.09 771 5.33%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 BNP Paribas 47,043.60 195 6.55%
2 JPMorgan 46,108.71 102 6.42%
3 UniCredit 39,106.98 168 5.45%
4 Credit Agricole CIB 36,670.04 182 5.11%
5 SG Corporate & Investment Banking 35,773.91 138 4.98%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 JPMorgan 14,088.48 62 8.97%
2 Goldman Sachs 13,469.15 66 8.57%
3 Citi 9,948.21 58 6.33%
4 Morgan Stanley 8,572.10 54 5.46%
5 UBS 8,391.04 36 5.34%